YD Bio (YDES) Non-Current Deferred Tax Liability (2024)

YD Bio (YDES) posted quarterly Non-Current Deferred Tax Liability of $1.5 billion for Q4 2024.

YD Bio (YDES) Non-Current Deferred Tax Liability (2024) Analysis & Trends

YD Bio (YDES) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $1.5 billion the latest figure, recorded in Q4 2024.

In Q4 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.5 billion; the TTM figure through Dec 2024 stood at $1.5 billion (changed N/A YoY), while the FY2024 annual figure was $1.5 billion, changed N/A from the prior year.
Non-Current Deferred Tax Liability held at $1.5 billion in Q4 2024 per YDES's latest filing.
Across five years, Non-Current Deferred Tax Liability topped out at $1.5 billion in Q4 2024 and bottomed at $1.5 billion in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	YD Bio	314.91 Mn	308.91 Mn	-

Download Data

Date	Value
Dec 31, 2024	1.46 Bn
Dec 31, 2024	1.46 Bn